Reducing visceral adiposity has been shown to improve insulin sensitivity, lipid profiles, and inflammatory markers, making it a critical therapeutic target in metabolic disease management
The GLP-1 mechanism is also found in other weight loss treatments such as Ozempic, Rybelsus, Saxenda (semaglutide), and Maunjaro (tirzepatide)
Premixed insulin may offer convenience for some but reduces treatment flexibility
But perhaps they have been too excited about it
Examples include AstraZenecas investment in Eccogene and Roches agreement to buy GLP-1 drug developer Carmot Therapeutics for up to $3.1bn in December 2023
it is essential for maintaining a healthy metabolism, keeping balance as you age, and maintaining bone density